Inhibrx Biosciences Will Present Data at Three Conferences
The biopharmaceutical company will showcase clinical research at major international medical meetings starting October 25, 2026.
Updated on Oct. 13, 2026 in Cancer
Inhibrx Biosciences is set to present new clinical, efficacy, and survival data at three upcoming scientific conferences in late 2026. The presentations will occur in Madrid, Miami, and Seoul between October 25 and November 20.
Why it matters
Sharing clinical results at major medical congresses is a critical milestone for biopharmaceutical firms, as it allows for peer review and visibility among global oncology experts. These updates provide the research community and stakeholders with the latest information on the company's therapeutic pipelines.
Inhibrx Biosciences recently executed a transaction where 92% of company shares were distributed to stockholders. Full details regarding the clinical trial methodologies and participant demographics remain under investigation until the presentations occur.
The players
Inhibrx Biosciences
This is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic proteins to treat oncology and rare diseases.
The details
The clinical-stage biopharmaceutical firm will unveil findings across three distinct events held in different global regions. Results will be made available to the public on the company's official investor portal following each presentation.
Timeline
October 25, 2026: Oral presentation at the ESMO Congress in Madrid, Spain.
October 29, 2026: Oral presentation at the MSTS Annual Meeting in Miami, Florida.
November 19, 2026: Poster presentation at the CTOS Annual Meeting in Seoul, South Korea.
November 20, 2026: Oral presentation at the CTOS Annual Meeting in Seoul, South Korea.
The Big Picture
The ESMO Congress serves as a premier venue for international scientific communication in the oncology sector. This release aligns with the industry standard of vetting new therapeutic data through presentation at established global medical institutions.
The data revealed at these conferences helps clarify the potential future treatment options available for patients with rare diseases. Stakeholders and observers can track these developments to better understand the progress of new medical therapies currently moving through the pipeline.
The takeaway
These upcoming presentations represent a pivotal window for investors and the medical community to assess the company's research trajectory. Interested parties should monitor the corporate website to access full reports immediately following the conclusion of each event.
What happens next
Inhibrx Biosciences will present clinical data at the ESMO Congress on October 25, 2026, followed by an efficacy presentation at the MSTS Annual Meeting on October 29, 2026, and a final presentation on November 19-20, 2026, at the CTOS Annual Meeting.
Further reading
For more on the current landscape of oncology research, visit the Cancer section.
More information
View the schedule and research updates on the Inhibrx investor events and presentations page.
